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With interest, we read the paper of Poillon et al. about
he possible association between the development of cerebral
enous thrombosis and coronavirus disease-2019 (COVID-19) [1].
lthough the authors mentioned that severe acute respiratory
yndrome coronavirus 2 (SARS-CoV-2) can cause hyperactivation
f inflammatory factors and damage to the coagulation system,
ncreasing the risk of deep vein thrombosis, cerebral venous throm-
osis and pulmonary embolism, the underlying pathogenesis was
ot discussed in detail. For this reason, we want to highlight in
he present manuscript the potential underlying pathophysiolog-
cal mechanisms of these virus infection-related thromboembolic
vents.
A substantial proportion (5–15%) of patients with severe COVID-
9 develop venous and arterial thromboembolic complications
2]. As an example, several recent papers have reported a cere-
ral venous thrombosis as an initial presentation of COVID-19
1,3,4]. These phenomena are probably related to a combination
f low-grade disseminated intravascular coagulation (DIC) and a
ocalised pulmonary thrombotic microangiopathy. The COVID-19
oagulopathy is characterised by an increased amount of D-dimers,
 high fibrinogen, a mildly prolonged prothrombin time, and a mod-
st thrombocytopenia. Although this picture could be suggestive for
 DIC, the diagnosis of DIC, according to the DIC score of the Interna-
ional Society on Thrombosis and Haemostasis, is often not retained
n patients with a SARS-CoV-2 infection as the level of D-dimers is
emarkably higher and the consumption of platelets is lower than
n e.g. sepsis-induced coagulopathy. Besides, increased concentra-
ions of lactate dehydrogenase and ferritin are often measured, as
een in patients with thrombotic microangiopathy. The hyperco-
gulable state in COVID-19 is illustrated by post-mortem findings,
.g. microvascular platelet-rich thrombotic depositions in the small
essels of the lungs. However, signs of hemolysis or schistocytes in
he blood film are absent and a higher platelet count is measured in
omparison to thrombotic microangiopathy [5]. Antiphospholipid
ntibodies can arise transiently and may  also play a yet unresolved
ole in the pathophysiology of thrombosis associated with COVID-
9 [6].Please cite this article in press as: Speeckaert MM,  et al, Potential un
with COVID-19, J Neuroradiol (2020), https://doi.org/10.1016/j.neurad
Looking at the underlying mechanisms for developing throm-
osis, the three criteria of Virchow’s triad (stasis, endothelial
njury or vessel wall injury, and hypercoagulability) are fulfilled
n critically ill COVID-19 patients. More specifically, immobility
[
[
https://doi.org/10.1016/j.neurad.2020.06.009
150-9861/© 2020 Elsevier Masson SAS. All rights reserved.and prone position result in reduced venous flow [6]. Hypoxia
leads to vasoconstriction and reduced blood flow, contributing
to endothelial dysfunction. Besides, the basal anti-inflammatory
and antithrombotic phenotype of the endothelium can be changed
into a proinflammatory and procoagulant phenotype by the alter-
ation of transcriptional factors [e.g. hypoxia-inducible factor 1
(HIF-1) and early growth response gene 1 (Egr1)] as previously
reported in other acute respiratory distress syndromes (ARDS) [2].
In severely COVID-19 cases, a “cytokine storm” with high concen-
trations of proinflammatory cytokines and chemokines [tumour
necrosis factor- (TNF-) and interleukins (IL), including IL-1
and IL-6] suppress anticoagulant pathways, release ultralarge von
Willebrand factor multimers and can induce tissue factor (TF)
expression. Neutrophils, monocytes, platelets and microparticles
in the circulation bind to the activated endothelium and local pro-
vide TF and neutrophils extracellular traps (NETs) for initiation of
coagulation via the TF/FVIIa pathway. This results in the generation
of excessive amounts of thrombin with a subsequent formation of
e.g. pulmonary microthrombotic vaso-occlusions. The hypercoag-
ulable state is further achieved by an imbalance between increased
procoagulant factors (e.g. fibrinogen, FV, and FVIII) and potentially
decreased or normal natural coagulation inhibitors (e.g. proteins C
and S, and antithrombin) [2,7].
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